Smoking Cessation Clinical Trials

"THE VERTIS CV STUDY" Type 2 Diabetes Mellitus and Established Vascular Disease Merck and Pfizer Announce Two Pivotal Phase 3 Studies for Ertugliflozin, an Investigational SGLT-2 Inhibitor, Met Primary Endpoints, Showing Significant A1C Reductions in Patients with Type 2 Diabetes http://www.mercknewsroom.com/news-release/corporate-news/merck-and-pfizer-announce-two-pivotal-phase-3-studies-ertugliflozin-inve

A Randomized, Double-Blind, Multi-Center, Parallel Group Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 on COPD Exacerbations over a 52-Week Treatment Period in Subjects With Moderate to Very Severe COPD. ClinicalTrials.gov identifier: NCT02465567 https://www.pearltherapeutics.com/pipeline-overview

The purpose of this research study is to test whether two different treatments can help smokers quit smoking. the first program is only for the smoker, while the other program will involve the smoker and their non-smoking romantic partner. Participants will attend one of the 8-week programs and receive the ...

The purpose of this study is to learn more about how a medication affects smoking.

If you’re taking High Cholesterol medication, you may qualify for a research study. Investigational medication provided at no charge Study-related care from a local doctor at no charge

Researchers with the University of Kentucky College of Medicine, Department of Behavioral Science are recruiting tobacco smokers to participate in a research study on behavioral and mental performance. All information obtained will be kept confidential.

Researchers at the University of Kentucky Department of Otolaryngology – Head and Neck Surgery and the Graduate Center for Toxicology are conducting a research study to gather data on the immediate and long term effects of exposure to cigarette smoke. The goal of this study is to see how exposure ...

We are currently recruiting smokers who are really motivated to quit smoking. The purpose of the study is to evaluate the safety and effectiveness of three approved medications, Habitrol, Zyban and Chantix, in combination and compared to a placebo (no active ingredient). Requires 12 weekly visits. Patient Inclusion Criteria: Participants ...

For more information please visit: http://clinicaltrials.gov/ct2/show/NCT01434342?term=CCCWFU+99211&rank=1

Patient Inclusion Criteria: Healthy male & female subjects between the ages of 12 and 19 years, inclusive Subjects must be currently smoking at least an average of 5 cigarettes per day during the past 30 days Subjects must have had at least 1 prior failed attempt to quit smoking Patient ...